|
Post by afrizzle on Apr 30, 2015 6:39:36 GMT -5
AF on suicide watch?
|
|
|
Post by liane on Apr 30, 2015 6:53:15 GMT -5
All the numbers in the table were reported rounded to the nearest million €. So Afrezza sales would be between 500,000 and 1,500,000 €.
€ million Q1 2015 net sales Change(CER) Lantus® 1,584 -5.0% Amaryl® 97 +1.2% Apidra® 91 +10.7% Insuman® 33 +3.1% BGM (Blood Glucose Monitoring) 16 +0.0% Lyxumia® 8 +60.0% Toujeo® 7 - Afrezza® 1 -
|
|
|
Post by kball on Apr 30, 2015 7:37:46 GMT -5
In the report, toujoe is being mentioned as (among) significant launch, afrezza just plain launch. Wonder what is the difference?"Launched" may be too strong a word. How does everyone feel if we dial it back a bit and maybe use "released" or even "escaped" to describe it? Like a prisoner, rather than a rocket.
|
|
|
Post by mnholdem on Apr 30, 2015 7:44:27 GMT -5
Why? Adam estimated 1st Quarter sales would be less than $250K, but he can easily slither away by simply claiming, "how can anybody know what will happen during the first few weeks after a launch?"
Frankly, if he does address his error (I doubt he will) I expect him to throw that line back into the faces of his detractors, since it was the most common complaint in the responses to his articles published opinions.
|
|
|
Post by brentie on Apr 30, 2015 8:15:31 GMT -5
For anybody who's interested, the Q&A is going on now and can be accessed with the above link.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 30, 2015 8:16:04 GMT -5
Like Ben mentioned, the toujeo numbers were to fill out warehouses. It's safe to assume the same thing for afrezza which would mean pull was pretty close to warehouse inventory. I.e SNY has a good idea how this would launch
|
|
|
Post by cusop on Apr 30, 2015 8:30:17 GMT -5
The significant event is that the the 1 € = to 1.1 million in dollars and from this one can estimate a correlation. Between symphony data and there claims, which means that there will be a boost at some point as the estimates produced by symphony is correlated to actuals ..
Also the Euro exchange rate was probably set by Sanofi at the beginning of there financial year which may mean the number is slight ly bigger..
this means investors in a kind have little to worry about, and once the full launch occurred we will see how the drug is really doing.
So hold tight and continue to wait
|
|
|
Post by cybergym66 on Apr 30, 2015 8:42:33 GMT -5
Better to paste here the "article" vs us clicking on the link and paying AF for his "analysis"...
|
|
|
Post by otherottawaguy on Apr 30, 2015 9:08:26 GMT -5
MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales By Adam Feuerstein Follow | 04/30/15 - 06:51 AM EDT
PARIS (TheStreet) -- Sales of MannKind's (MNKD) inhaled insulin Afrezza totaled €1 million in the first quarter of its commercial launch, marketing partner Sanofi (SNY - Get Report) reported Thursday. Afrezza sales reported by Sanofi presumably includes inventory stocking, but the company did not break down the results further. Sanofi began selling Afrezza in early February.
In today's dollars, Afrezza sales were just over $1.1 million in the quarter, well below the MannKind analyst consensus target in the range of $3 million to $4 million. The Afrezza sales miss was anticipated, however, based on generally weak prescription numbers compiled by tracking services like IMS Health.
Asked to assess the nascent Afrezza launch, a Sanofi spokesperson said, "The initial rollout of Afrezza is targeted and focused on building awareness behind the product and appropriate usage. Because of requirements imposed by the FDA for starting patients on this therapy and the necessary time to gain market access, it will take time for Afrezza to demonstrate its potential. Additional activities planned for 2015 include a direct-to-consumer campaign and the launch of the 12-unit cartridge planned for the second half of 2015."
Sanofi's total diabetes sales were €1.84 billion in the quarter, a decrease of 3.2% from the previous year. The company said diabetes sales would likely fall approximately 3% for the remainder of the year due to competition and pricing pressure in the U.S. Previously, Sanofi expected sales in its diabetes unit to remain "broadly stable" in 2015.
Sales of the insulin product Lantus, Sanofi's biggest, fell 5% to €1.6 billion, reflecting lower sales in the U.S. Lantus loses patent protection later this year. Sales of newly launched insulin Toujeo were €7 million.
Overall, Sanofi earnings in the first quarter rose 2.6% on a constant basis, or almost 13% when favorable currency exchange rates are factored in. Sales rose 2.4% on a constant basis, or 12.3% with currency factored in. The company's results exceeded analyst expectations.
|
|
|
Post by cubonwallstreet on Apr 30, 2015 9:30:48 GMT -5
I am a very patient person and rarely let people get under my skin. And I am completely aware there are powers above him giving orders. But I sure would love to meet Adam in a dark alley.
|
|
|
Post by newmnkdinvestor on Apr 30, 2015 9:37:19 GMT -5
He doesn't look like much of a competition if you met him in a dark alley.
IMO how frustrated can we get when the numbers are just not there. Afrezza is making his job easier. The numbers are the only thing that will shut them up.
|
|
|
Post by newmnkdinvestor on Apr 30, 2015 9:37:54 GMT -5
A wet noodle launch as even soft is too generous
|
|
|
Post by dstevenson on Apr 30, 2015 9:38:06 GMT -5
52 week low...seriously
|
|
|
Post by yossarian on Apr 30, 2015 10:41:54 GMT -5
Even Adam in a backhanded way recognizes that AFREZZA sales are greater than reported by Symphony and IMS, actually more than double. Guy's being pulled along by the scruff of his neck.
|
|
|
Post by dreamboatcruise on Apr 30, 2015 11:08:14 GMT -5
At the moment, MNKD will look to take around $18-20MM for manufacturing from Q1. The profit share from the partnership is a tricky one as they may not realize anything from it for a while and needs someone above my paygrade to work that one out. As it currently stands, it wouldn't be much more than 250k in the best case scenario. You aren't expecting profit this soon are you? Remember MNKD shares in losses as well. Early on the costs will exceed revenue and MNKD will be booking its 35% share of loss. That could be offset and turned into overall profit for MNKD if they start recognizing some of the upfront payments as accrued revenue rather than holding them on balance sheet as unearned prepayments... but we haven't been given details about that.
|
|